Reversal of multidrug resistance: Lessons from clinical oncology

Novartis Foundation Symposium

Volumn 243, Issue , 2002, Pages 83-102

  Bates, Susan E ^a   Chen, Clara ^a   Robey, Robert ^a   Kang, Min ^a   Figg, William D ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZAZEPINE DERIVATIVE; BIRICODAR; CYCLOSPORIN DERIVATIVE; DIAGNOSTIC AGENT; DIBENZO[A,D]CYCLOHEPTENE DERIVATIVE; ENZYME INHIBITOR; FLUORESCENT DYE; GLYCOPROTEIN P; LANIQUIDAR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; RHODAMINE; TARIQUIDAR; TUMOR PROTEIN; VALSPODAR; ZOSUQUIDAR;

ANIMAL; CELL CULTURE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; DRUG RESISTANCE; GENE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; MULTIDRUG RESISTANCE; NEOPLASM; PHYSIOLOGY; REVIEW; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAZEPINES; CLINICAL TRIALS; CYCLOSPORINS; DIBENZOCYCLOHEPTENES; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FLUORESCENT DYES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; PIPERIDINES; PYRIDINES; QUINOLINES; RADIOPHARMACEUTICALS; RHODAMINES; TECHNETIUM TC 99M SESTAMIBI; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0036355399     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (40)

1. Abraham J, Edgerley M, Wilson R et al 2001 A phase I study of the novel P-glycoprotein (Pgp) antagonist, XR9576 in combination with vinorelbine. Proc Am Soc Clin Oncol Annu Meet 37
2. Bakker M, van der Graaf WT, Piers DA et al 1999 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. Anticancer Res 19:2349-2353
3. Bates SE, Wilson WH, Fojo AT et al 1996 Clinical reversal of multidrug resistance. Stem Cells 14:56-63
4. Boote DJ, Dennis IF, Twentyman PR et al 1996 Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610-618
5. Chico I, Kang MH, Bergan R et al 2001 Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol 19:832-842
6. Dano K 1973 Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323:466-483
7. Desrayaud S, Guntz P, Scherrmann JM, Lemiare M 1997 Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmaconkinetics of colchicine. Life Sci 61:153-163
8. Ferry DR, Traunecker H, Kerr DJ 1996 Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A:1070-1081
9. Fisher GA, Sikic BI 1995 Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9:363-382
10. Fracasso PM, Westerveldt P, Fears CA et al 2000 Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J Clin Oncol 18:1124-1134
11. Giaccone G, Linn SC, Welink J et al 1997 A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3:2005-2015
12. Hoffmeyer S, Burk O, von Richter O et al 2000 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478
13. Kang YK, Zhan Z, Regis J et al 1995 Expression of MDR-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood 86:1515-1524
14. Kartner N, Riordan JR, Ling V 1983 Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285-1288
15. Kovarik JM, Purba HS, Pongowski M, Gerbeau C, Humbert H, Mueller EA 1998 Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (MDR1) modulator: implications for coadmmistration. Pharmacotherapy 18:1230-1236
16. Krishna R, Mayer LD 1997 Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in-effective therapy of multidrug-resistant solid tumors. Cancer Res 57:5246-5253
17. Luker GD, Facasso PM, Dobkin J, Piwnica-Worms D 1997 Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. J Nucl Med 38:369-372
18. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH 1997 Full blockage of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC 833. J Clin Invest 100:2430-2436
19. Peck RA, Marshall J, Ziessman H et al 1996 A Phase I trial of doxorubicin and VX-710. Proc Am Assoc Cancer Res 87
20. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM 1993 Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977-984
21. + cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood 93:306-314
22. i homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry 32:11042-11056
23. Rowinsky EK, Smith L, Wang YM et al 1998 Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16:2964-2976
24. Sandor V, Fojo T, Bates SE 1998 Future perspectives for the development of P-glycoprotein modulators. Drug Resist Updates 1:190-200
25. Schinkel AH, Smit JJ, van Tellingen O et al 1994 Disruption of mouse Mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502
26. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P 1995 Absence of the Mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705
27. Schinkel AH, Wagenaar E, Mol CA, van Deemter L 1996 P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524
28. Schinkel AH, Mayer U, Wagenaar E et al 1997 Normal viability and altered pharmacokinetics in mice lacking Mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033
29. Solary E, Velay I, Chauffert B et al 1991 Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68:1714-1719
30. Solary E, Witz B, Caillot D et al 1996 Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 88:1198-1205
31. Sonneveld P, Marie JP, Huisman C et al 1996 Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 10:1741-1750
32. Sparreboom A, Planting AS, Jewell RC et al 1999 Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 10:719-728
33. Tew KD, Houghton PJ, Houghton JA 1993 Preclinical and clinical modulation of anticancer drugs. CRC Press, Boca Raton
34. Thummel KE, Shen DD, Podoll TD et al 1994 Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271:557-566
35. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y 1981 Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhancing cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972
36. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O 1996 Altered pharmacokinetics of vinblastine in Mdr1 a P-glycoprotein-deficient mice. J Natl Cancer Inst 88:994-999
37. van Asperen J, van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH 1999 Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking Mdr1a P-glycoprotein. Br J Cancer 79:108-113
38. van Zuylen L, Sparreboom A, van der Gaast A et al 2000 The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 6:1365-1371
39. Wilson WH, Berg SL, Bryant G et al 1994 Paclitaxel in doxorubicin-refractory or mitoxantrone refractory breast cancer: a phase 1/11 trial of 96-hour infusion. J Clin Oncol 12:1621-1629
40. Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS 1996 Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 2:7-12